Skip to content
Search

Latest Stories

Parkinson's may be detectable 20-30 years before clinical diagnosis: Study

According to the researchers, the disease, often thought of as an illness of old age, in fact, starts in midlife and can go undetected for decades

Parkinson's may be detectable 20-30 years before clinical diagnosis: Study

Signs of Parkinson's disease could potentially be identified 20-30 years before symptoms appear, Australian researchers have said.

Utilising a biomarker named F-AV-133 in combination with PET (positron emission tomography) scans enables the diagnosis of Parkinson's disease and precise monitoring of neurodegeneration, researchers from the Florey Institute of Neuroscience and Mental Health in Melbourne said.


F-AV-133 is an imaging agent and has shown promise as a PET tracer for detecting and monitoring neurodegeneration in Parkinson's disease, a progressive neurological disorder characterised by tremors and impaired muscular coordination.

According to the researchers, the disease, often thought of as an illness of old age, in fact, starts in midlife and can go undetected for decades.

"Parkinson's disease is very hard to diagnose until symptoms are obvious, by which time up to 85 per cent of the brain's neurons that control motor coordination have been destroyed. At that point, many treatments are likely to be ineffective," said Kevin Barnham, professor at The Florey and lead researcher of the study published in the journal Neurology.

In their study, 26 patients already diagnosed to have Parkinson's disease and a control group of 12 people were scanned, along with 11 other people having Rapid Eye Movement sleep behaviour disorder (RBD), a strong indicator of the disease. All of them undertook two PET scans two years apart.

The researchers found that the PET scans showed a significant loss in the nerve cells or neurons in three key regions of the brain in individuals with the disease, even as no significant changes in their clinical symptoms were seen according to currently available diagnostic assessments.

The findings suggest that F-AV-133 is a more sensitive means of monitoring neurodegeneration than what is now available, the researchers said in their study.

Using mathematical modelling, they found that when clinical symptoms of the disease begin to show and are sufficient for diagnosis, approximately 33 years' worth of slow neuronal loss has already taken place.

However, only about 10.5 years' worth of this neuronal loss happens before the disease can be detected on a PET scan, they said. Thus, they say that this diagnostic technique could help detect Parkinson's disease more than 20 years sooner than clinical diagnosis.

RBD is a significant warning sign for early Parkinson's disease and people having RBD are known to often shout or thrash around, sometimes violently, in their sleep while acting out vivid and unpleasant dreams.

About half of people with Parkinson's have RBD and roughly 90 per cent of people with RBD are likely to develop a parkinsonian condition. If one has RBD, it is suggested that they consult with a sleep specialist or a neurologist.

(PTI)

More For You

Crispello Comeback: Cadbury’s Light Treat Hits B&M Shelves

The return to UK shelves has brought a wave of nostalgia for many

Getty

Cadbury Crispello chocolate bars return to UK shelves at B&M for 49p

Cadbury's Crispello chocolate bars have made a surprise return to UK stores, now available at B&M for just 49p. The product, a mix of light wafer and smooth chocolate, had previously been discontinued in the UK and was only available overseas in recent years.

Each individual pack of Crispello contains four chocolate-covered wafer fingers, filled with a creamy chocolate centre. The sweet treat has gained attention on social media, with shoppers expressing their excitement about its reappearance in British stores.

Keep ReadingShow less
 Sharon Osbourne

Celebrities including Sharon Osbourne and Oprah Winfrey might be exhibiting signs of this side effect

Instagram/ Sharonosbourne

‘Ozempic feet’ joins growing list of unusual side effects linked to popular weight-loss drug

Ozempic, the blockbuster weight-loss medication that has surged in popularity across the United States and among celebrities, is now being linked to a new and unexpected side effect like sagging skin on the feet, informally dubbed “Ozempic feet”.

Medical experts say the condition is caused by rapid fat loss, which not only alters the appearance of the face and buttocks, but can also lead to aesthetic changes in the feet. As the drug continues to make headlines for its weight-loss benefits, concerns about such side effects are also gaining attention.

Keep ReadingShow less
MRI

Individuals with certain metabolic conditions may be more prone to this process

Getty

MRI injection linked to rare deadly health risk, study finds

A new study has raised concerns over the use of a common chemical injected during MRI scans, suggesting it may contribute to a potentially fatal complication in rare cases.

Researchers from the University of New Mexico have found that gadolinium – a toxic rare earth metal used in MRI contrast agents – can interact with oxalic acid found in many foods to form nanoparticles in human tissues. These particles could potentially lead to serious health problems affecting organs such as the kidneys.

Keep ReadingShow less
Morrisons

Morrisons has said it will continue to monitor customer feedback

Getty

Morrisons adds charity donation option to More Card loyalty scheme

Morrisons has announced a new update to its More Card loyalty programme, giving customers the option to donate their points to charity. The change, introduced on Monday 14 April, allows shoppers to convert their saved points into cash donations for Marie Curie, a UK charity that provides end-of-life care and support.

Under the new scheme, customers can donate their points in multiples of 1,000, which equates to a £1 value. Donations can be made easily through the More Card app or the official Morrisons website. Once submitted, the points are converted into their cash equivalent and passed directly to Marie Curie on behalf of the customer.

Keep ReadingShow less